Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LM-350 in advanced solid tumors
NCT07112222Phase 2Recruiting
- Sponsor
- LaNova Medicines
- Start
- Aug 2025
- Primary completion
- Jun 2028
- Modality
- Antibody-Drug Conjugates (ADCs)
- Countries
- 2
01
Overview
A Phase 2 trial of LM-350 in malignant neoplasm, sponsored by LaNova Medicines. Started Aug 2025; status: recruiting.
02
Drugs
LM-350
03
Conditions
malignant neoplasm
Beyond the preview
Go deeper on NCT07112222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07112222.